Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
66-week extension study of MK-3102 in type 2 diabetes mellitus
2011-000656-42Phase 2Completed
- Sponsor
- MSD
- Start
- Feb 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of omarigliptin in type 2 diabetes mellitus (T2DM), sponsored by MSD. Primary endpoint: Safety and tolerability of MK-3102 over 66 weeks. Started Feb 2011; status: completed.
02
Drugs
omarigliptin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2011-000656-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-000656-42.